European public health specialists on Monday identified significant resistance to the drug Tamiflu, casting a shadow over the efficacy of the world’s most widely purchased influenza antiviral medicine.

The European Centres for Disease Control said that while Tamiflu could still provide benefits, 13 per cent of samples of the H1N1 seasonal flu virus affecting Europe tested last November and December – most in Norway – contained a mutation associated with high levels of resistance.